How significant is the association between metabolic syndrome
and prevalence of colorectal neoplasia?

J 2016

How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

SUCHANEK, Stepan; Tomas GREGA; Ondřej NGO; Gabriela VOJTECHOVA; Ondřej MÁJEK et al.

Základní údaje

Originální název

How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Autoři

SUCHANEK, Stepan; Tomas GREGA; Ondřej NGO; Gabriela VOJTECHOVA; Ondřej MÁJEK ; Petra MINARIKOVA; Nagyija BROGYUK; Bohus BUNGANIC; Bohumil SEIFERT; Ladislav DUŠEK a Miroslav ZAVORAL

Vydání

World Journal of Gastroenterology, Beijing, China, Baishideng, 2016, 1007-9327

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.365

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00088892

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.3748/wjg.v22.i36.8103

UT WoS

000383982700005

EID Scopus

2-s2.0-84991089523

Klíčová slova anglicky

Metabolic syndrome; Diabetes mellitus type 2; Heart ischemic disease; Colorectal neoplasia

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 11. 2016 12:29, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.

Návaznosti

NT13673, projekt VaV

Název: Cílený screening kolorektálního karcinomu u diabetiků 2. typu a osob s vysokým kardiovaskulárním rizikem: multicentrická prospektivní studie

Investor: Ministerstvo zdravotnictví ČR, Cílený screening kolorektálního karcinomu u diabetiků 2. typu a osob s vysokým kardiovaskulárním rizikem: multicentrická prospektivní studie

Citovat

SUCHANEK, Stepan; Tomas GREGA; Ondřej NGO; Gabriela VOJTECHOVA; Ondřej MÁJEK; Petra MINARIKOVA; Nagyija BROGYUK; Bohus BUNGANIC; Bohumil SEIFERT; Ladislav DUŠEK a Miroslav ZAVORAL. How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia? World Journal of Gastroenterology. Beijing, China: Baishideng, 2016, roč. 22, č. 36, s. 8103-8111. ISSN 1007-9327. Dostupné z: https://doi.org/10.3748/wjg.v22.i36.8103.

@article{1356789,
   author = {Suchanek, Stepan and Grega, Tomas and Ngo, Ondřej and Vojtechova, Gabriela and Májek, Ondřej and Minarikova, Petra and Brogyuk, Nagyija and Bunganic, Bohus and Seifert, Bohumil and Dušek, Ladislav and Zavoral, Miroslav},
   article_location = {Beijing, China},
   article_number = {36},
   doi = {https://doi.org/10.3748/wjg.v22.i36.8103},
   keywords = {Metabolic syndrome; Diabetes mellitus type 2; Heart ischemic disease; Colorectal neoplasia},
   language = {eng},
   issn = {1007-9327},
   journal = {World Journal of Gastroenterology},
   title = {How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?},
   volume = {22},
   year = {2016}
}

TY  - JOUR
ID  - 1356789
AU  - Suchanek, Stepan - Grega, Tomas - Ngo, Ondřej - Vojtechova, Gabriela - Májek, Ondřej - Minarikova, Petra - Brogyuk, Nagyija - Bunganic, Bohus - Seifert, Bohumil - Dušek, Ladislav - Zavoral, Miroslav
PY  - 2016
TI  - How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?
JF  - World Journal of Gastroenterology
VL  - 22
IS  - 36
SP  - 8103-8111
EP  - 8103-8111
PB  - Baishideng
SN  - 10079327
KW  - Metabolic syndrome
KW  - Diabetes mellitus type 2
KW  - Heart ischemic disease
KW  - Colorectal neoplasia
N2  - The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.
ER  -

SUCHANEK, Stepan; Tomas GREGA; Ondřej NGO; Gabriela VOJTECHOVA; Ondřej MÁJEK; Petra MINARIKOVA; Nagyija BROGYUK; Bohus BUNGANIC; Bohumil SEIFERT; Ladislav DUŠEK a Miroslav ZAVORAL. How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia? \textit{World Journal of Gastroenterology}. Beijing, China: Baishideng, 2016, roč.~22, č.~36, s.~8103-8111. ISSN~1007-9327. Dostupné z: https://doi.org/10.3748/wjg.v22.i36.8103.

Přehled o publikaci